|
5 Companies |
|
7 Products |
|
7 Products |
|
9 Mechanisms of Action |
|
0 Trials |
|
16 News |
|
- | Tasigna (nilotinib) / Novartis, Inhibikase
Enrollment change, Trial primary completion date, Metastases: NICAM: A Trial Looking at Nilotinib to Treat Acral and Mucosal Melanoma Skin Cancer That Has Spread (clinicaltrials.gov) - Jun 8, 2017
P2, N=29, Completed, Sponsor: Institute of Cancer Research, United Kingdom
N=24 --> 29 | Trial primary completion date: Jun 2012 --> Dec 2016
- || Sutent (sunitinib) / Pfizer
Trial primary completion date, Metastases: SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma (clinicaltrials.gov) - Jun 12, 2016
P2, N=52, Active, not recruiting, Sponsor: Dana-Farber Cancer Institute
N=24 --> 29 | Trial primary completion date: Jun 2012 --> Dec 2016 Trial primary completion date: Mar 2016 --> Jul 2014
- Sutent (sunitinib) / Pfizer
Trial primary completion date, Metastases: SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma (clinicaltrials.gov) - Jan 21, 2016
P2, N=50, Active, not recruiting, Sponsor: Dana-Farber Cancer Institute
Trial primary completion date: Mar 2016 --> Jul 2014 Trial primary completion date: Aug 2014 --> Mar 2016
- Recentin (cediranib) / AstraZeneca
Enrollment change, Metastases: AZD2171 in Treating Patients With Recurrent or Stage IV Melanoma (clinicaltrials.gov) - Jun 23, 2015
P2, N=24, Completed, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Aug 2014 --> Mar 2016 N=33 --> 24
- imatinib / Generic mfg.
Trial completion, Enrollment change, Surgery, Metastases: Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery (clinicaltrials.gov) - Dec 24, 2014
P2, N=30, Completed, Sponsor: National Cancer Institute (NCI)
N=33 --> 24 Active, not recruiting --> Completed | N=327 --> 30
- dasatinib / Generic mfg.
Trial termination: Treatment With Dasatinib in Patients With Acral Lentiginous, Mucosal, or Chronic Sun-damaged Melanoma (clinicaltrials.gov) - Aug 21, 2014
P2, N=19, Terminated, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed | N=327 --> 30 Completed --> Terminated; Slow accrual.
- | dasatinib / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date: Treatment With Dasatinib in Patients With Acral Lentiginous, Mucosal, or Chronic Sun-damaged Melanoma (clinicaltrials.gov) - Aug 19, 2014
P2, N=19, Completed, Sponsor: M.D. Anderson Cancer Center
Completed --> Terminated; Slow accrual. Active, not recruiting --> Completed | N=30 --> 19 | Trial primary completion date: May 2015 --> Aug 2014
- RG4733 / Roche
Enrollment change, Metastases: Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Stage IV Melanoma (clinicaltrials.gov) - Jun 8, 2014
P2, N=24, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed | N=30 --> 19 | Trial primary completion date: May 2015 --> Aug 2014 N=72 --> 24
- Sutent (sunitinib) / Pfizer
Enrollment closed, Metastases: SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma (clinicaltrials.gov) - Jan 5, 2014
P2, N=50, Active, not recruiting, Sponsor: Dana-Farber Cancer Institute
N=72 --> 24 Recruiting --> Active, not recruiting
- imatinib / Generic mfg.
Enrollment change, Surgery, Metastases: Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery (clinicaltrials.gov) - Jan 5, 2014
P2, N=327, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting N=50 --> 327
- | dasatinib / Generic mfg.
Enrollment closed: Treatment With Dasatinib in Patients With Acral Lentiginous, Mucosal, or Chronic Sun-damaged Melanoma (clinicaltrials.gov) - Sep 9, 2013
P2, N=30, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
N=50 --> 327 Recruiting --> Active, not recruiting
- Recentin (cediranib) / AstraZeneca
Enrollment change, Metastases: AZD2171 in Treating Patients With Recurrent or Stage IV Melanoma (clinicaltrials.gov) - May 6, 2013
P2, N=33, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting N=24 --> 33
- RG4733 / Roche
Enrollment closed, Metastases: Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Stage IV Melanoma (clinicaltrials.gov) - Apr 21, 2013
P2, N=72, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
N=24 --> 33 Completed --> Active, not recruiting
- imatinib / Generic mfg.
Enrollment closed, Surgery, Metastases: Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery (clinicaltrials.gov) - Mar 3, 2013
P2, N=327, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Completed --> Active, not recruiting Recruiting --> Active, not recruiting
- Recentin (cediranib) / AstraZeneca
Trial completion, Metastases: AZD2171 in Treating Patients With Recurrent or Stage IV Melanoma (clinicaltrials.gov) - May 30, 2012
P2, N=33, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Active, not recruiting --> Completed